Complete Regression of Cutaneous B-Cell Lymphoma in a Renal Transplant Patient After Conversion From Cyclosporin to Sirolimus

Transplantation Proceedings

Volumn 39, Issue 4, 2007, Pages 1267-1271

  Mohsin, N ^a   Budruddin, M ^a   Kamble, P ^a   Khalil, M ^a   Pakkyarra, A ^a   Jha, A ^a   Mohammed, E ^a   Ahmed, H ^b   Ahmed, J ^b   Thomas, S ^c   Campistol, J M ^d   Daar, A ^e  

^a ROYAL HOSPITAL   (Oman)

^b MINISTRY OF HEALTH   (Oman)

^c Department of Pathology ^*  (Spain)

^d HOSPITAL CLÍNIC   (Spain)

^e at the University of Toronto Wagner is also a faculty member of the Canadian Medical Associations' Physician Management Institute   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOSPORIN; GANCICLOVIR; GRANULOCYTE COLONY STIMULATING FACTOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RAPAMYCIN; VALGANCICLOVIR;

ACINETOBACTER; ADULT; ARTICLE; B CELL LYMPHOMA; CASE REPORT; CYTOMEGALOVIRUS INFECTION; DISEASE SEVERITY; DRUG BLOOD LEVEL; FOLLOW UP; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN TISSUE; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; LEUKOPENIA; MALE; PNEUMOCYSTOSIS; PNEUMONIA; PRIORITY JOURNAL; SKIN LYMPHOMA;

BIOPSY; CYCLOSPORINE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LYMPHOMA, B-CELL; MALE; MIDDLE AGED; NEOPLASM REGRESSION, SPONTANEOUS; SIROLIMUS; SKIN NEOPLASMS;

EID: 34248517202     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2007.03.092     Document Type: Article

References (53)

1. Friedberg J.W., Jessup M., and Brennan D.C. Lymphoproliferative disorders following solid organ transplantation. In: Rose B.D. (Ed). UpToDate (2006) Waltham, MA
2. Caillard S., Dharnidharka V., Agodoa L., et al. Posttransplant lymphoproliferative disorders after renal transplantation in the United States in era of modern immunosuppression. Transplantation 80 (2005) 1233
3. Paya C.V., Fung J.J., Nalesnik M.A., et al. Epstein-Barr Virus-induced posttransplant lymphoproliferative disorders. Transplantation 68 (1999) 1517
4. Caillard S., Agodoa L.Y., Bohen E.M., et al. Myeloma, Hodgkin disease, and lymphoid leukemia after renal transplantation. Transplantation 81 (2006) 888
5. Cockfield S.M., Preiksaitis J.K., Jewell L.D., et al. Post-transplant lymphoproliferative disorder in renal allograft recipient. Clinial experience and risk factor analysis in a single center. Transplantation 56 (1993) 88
6. Tsai D.E., Hardy C.L., Tomaszewski J.E., et al. Reduction in immunosuppression as initial therapy for post transplant lymphoproliferative disorder: analysis of prognostic variables and long-term followup of 42 adult patients. Transplantation 71 (2001) 1076
7. Kahan B.D., Yakupoglu Y.K., Schoenberg L., et al. Low incidence of malignancy among Sirolimus/cyclosporine-treated renal transplant recipients. Transplantation 80 (2005) 749
8. Brennan D.C., Rodeheffer R.J., and Ambinder R.F. Development of malignancy following solid organ transplantation. In: Rose B.D. (Ed). UpToDate (2006) Waltham, MA
9. Rubio-Viqueira B., and Hidalgo M. Targeting mTOR for cancer treatment. Curr Opin Investig Drugs 7 (2006) 501
10. Dancey J.E. Therapeutic targets: mTOR and related pathways. Cancer Biol Ther 5 (2006) Epub
11. Khariwala S.S., Kjaergaard J., Lorenz R., et al. Everolimus (RAD) inhibits in vivo growth of murine squamous cell carcinoma (SCC VII). Laryngoscope 116 (2006) 814
12. Namba R., Young L.J., Abbey C.K., et al. Rapamycin Inhibits growth of premalignant and malignant mammary lesions in a mouse model of ductal carcinoma in situ. Clin Cancer Res 12 (2006) 2613
13. Brown V.I., Fang J., Alcorn K., et al. Rapamycin is active against B-precusor leukemia in vitro and in vivo an effect that is modulated by IL-7 mediated signaling. Proc Natl Acad Sci U S A 100 (2003) 15113
14. Sin S.H., Roy D., Wang L., et al. Rapamycin is efficacious against primary effusion lymphoma (PEL) cell lines in vivo by inhibiting autocrine signaling. Blood Nov (Epub) (2006)
15. Sirolimus inhibits tumor growth of cholangiocarcinoma in vitro and in vivo and combination with gemcitaabine improves efficacy of gemcitabine alone. Transplantation 82 1 suppl 2 (2006) 1007
16. Wienecke R., Fackler I., Linsenmaier U., et al. Antitumoral activity of rapamycin in renal angiomyolipoma associated with tuberous sclerosis complex. Am J Kidney Disease 48 (2006) E27
17. Stallone G., Schena A., Infante B., et al. Sirolimus for Kaposi's sarcoma in renal transplant recipients. N Engl J Med 352 (2005) 1317
18. Campistol J.M., Gutierrez-Dalmau A., and Torregrosa J.V. Conversion to sirolimus: a successful treatment for post transplantation Kaposi's sarcoma. Transplantation 77 (2004) 760
19. Zmonarski S.C., Boratynska M., Rabcznski J., et al. Regression of Kaposi's sarcoma in renal graft recipients after conversion to sirolimus treatment. Transplant Proc 37 (2005) 964
20. Mohsin N., Budruddin M., Pakkyara A., et al. Complete regression of visceral Kaposi's sarcoma after conversion to sirolimus. Experimental and Clinical Transplantation 2 (2005) 366
21. Campistol J.M., Eris J., Oberbauer R., et al. Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. J Am Soc Nephrol 17 (2006) 581
22. Kaufman H.M., Cherikh W.S., Mc Bride M.A., et al. Post-transplant de novo malignancies in renal transplant recipients: the past and present. Transpl Int 19 (2006) 607
23. Kaufman H.M., Cherikh W.S., Cheng Y., et al. Maintenance Immunosuppression with target-of rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation 80 (2005) 883
24. Opelz G., and Henderson R. Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients. Lancet 342 (1993) 1514
25. Caillard S., Dharnidharka V., Agodoa, et al. post transplant lymphoproliferative disorders after renal transplantation in the United States in era of modern immunosuppression. Transplantation 80 (2005) 1233
26. Ghobrial I.M., Habermann T.M., Maurer M.J., et al. Prognostic analysis for survival in adult solid organ transplant recipients with Post-transplantation lymphoproliferative disorders. J Clin Oncol 23 (2005) 7574
27. Smith J.M., Rudser K., Gillen D., et al. Risk of lymphoma after renal transplantation varies with time: an analysis of the United States Renal Data System. Transplantation 81 (2006) 175
28. Rajakariar R., Bhattacharyya M., Norton A., et al. MM: Post transplant T-cell lymphoma: a case series of four patients from a single unit and review of the literature. Am J Transplant 4 (2004) 1534
29. Petit B., Le Meur Y., Jaccard A., et al. Influence of host- recipient origin on clinical aspects of posttransplantation lymphoproliferative disorders in kidney transplantation. Transplantation 73 (2002) 265
30. Stevens S.J., Verschuuren E.A., Pronk I., et al. Frequent monitoring of Epstein-Barr virus DNA load in unfractionated whole blood is essential for early detection of post transplant lymphoproliferative disease in high-risk patients. Blood 97 (2001) 1165
31. Green M., Bueno J., Rowe D., et al. Predictive negative value of persistent low Epstein-Barr virus viral load after intestinal transplantation in children. Transplantation 70 (2000) 593
32. Wagner H.J., Wesel M., Jabs W., et al. Patients at risk for development of posttransplant lymphoproliferative disorders: plasma versus peripheral blood mononuclear cell as material for quantification of Epstein Barr viral load by using real-time quantitative polymerase chain reaction. Transplantation 72 (2001) 1012
33. Zangwill S.D., Hsu D.T., Kichuk M.R., et al. Incidence and outcome of primary Epstein-Barr infection and lymphoproliferative disease in pediatric heart transplant recipients. J Heart Lung Transplant 17 (1998) 1161
34. McDiarmid S.V., Jordan S., Kim G.S., et al. Prevention and preemptive therapy of posttransplant lymphoproliferative disease in pediatric liver recipients. Transplantation 66 (1998) 1604
35. Hanto D.W. Classification of Epstein-Barr virus-associated posttransplant lymphoproliferative diseases: implications for understanding their pathogenesis and developing rational treatment strategies. Annu Rev Med 46 (1995) 381
36. Liebowitz D. Epstein-Barr virus and a cellular signaling pathway in lymphomas from immunosuppressed patients. N Engl J Med 338 (1998) 1413
37. Mosialos G., Birkenbach M., Yalamanchilli R., et al. The Epstein-Barr virus transforming protein LMP1 engages signaling proteins for the tumor necrosis factor receptor family. Cell 80 (1995) 389
38. Thaunat O., and Morelon E. Cancer and immunosuppression: pro-and antitumoral effects of immunosuppressive drugs). Nephrol Ther 1 (2005) 23
39. Guba M., Graeb C., Jauch K.W., et al. pro-and anti cancer effects of immunosuppressive agents used in organ transplantation. Transplantation 77 (2004) 1777
40. Muthukkumar S., Ramesh T.M., and Bondada S. Rapamycin, a potent immunosuppressive drug, causes programmed cell death in B lymphoma cells. Transplantation 60 (1995) 264
41. Dantal J., and Soulillou J.P. Immunosuppressive drugs and the risk of cancer after organ transplantation. N Engl J Med 352 (2005) 1371
42. Andreone P., Gramenzi A., Lorenzini S., et al. Posttransplantation lymphoproliferative disorders. Arch Intern Med 163 (2003) 1997
43. Luan F.L., Hojo M., Maluccio M., et al. Rapamycin blocks tumor progression: unlinking immunosuppression from antitumor efficacy. Transplantation 73 (2002) 1565
44. Zhou J., Fan J., Wang Z., et al. Conversion to sirolimus immunosuppression in liver transplantation recipient with hepatocellular carcinoma: report of an initial experience. World J Gastroenterol 12 (2006) 3114
45. Tsai D.E., Hardy C.L., Tomaszewski J.E., et al. Reduction in immunosuppression as initial therapy for post transplant lymphoproliferative disorder: analysis of prognostic variables and long term follow-up of 42 patients. Transplantation 71 (2001) 1076
46. Datta A.K., Colby B.M., Shaw J.E., et al. Acyclovir inhibition of Epstein-Barr virus replication. Proc Natl Acad Sci U S A 77 (1980) 5163
47. MacMahon E.M. More on virostatic therapy for advanced lymphoproliferation associated with Epstein- Barr virus in an HIV-infected patient. N Engl J Med 343 (2000) 71
48. Davis C.L., Wood B.L., Sabath D.E., et al. Interferon-alpha treatment of posttransplant lymphoproliferative disorder in recipient of solid organ transplants. Transplantation 66 (1998) 1770
49. Gonzalez-Barca E., Domingo-Domenech E., Gomez-Codina J., et al. First-line treatment with Rituximab improves survival of patients with post transplant lymphoproliferative disease (PTLD). Blood 104:Abstract (2004)
50. Choquet S., Leblond V., Herbrecht R., et al. Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study. Blood 107 (2006) 3053
51. Cullis B., D'Souza R., McCullagh P., et al. Sirolimus-induced remission of posttransplantation lymphoproliferative disorder. Am J Kidney Dis 47 (2006) E67
52. Jimenez-Rivera C., Avitzur Y., Fecteau A.H., et al. Sirolimus for pediatric liver transplant recipients with post transplant lymphoproliferative disease and hepatoblastoma. Pediatr Transplant 8 (2004) 243
53. Zaltzman J.S., Prasad R., Chun K., et al. Resolution of renal allograft-associated post-transplant lymphoproliferative disorder with the introduction of Sirolimus. Nephrol Dial Transplant 20 (2005) 1748